Phase 3 Start

LRMR: Phase3_Start: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia

Name: Phase3_Start: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia
Start: 2026-10-26
End: 2026-10-26

October 26, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: October 26, 2026
Company: Larimar Therapeutics, Inc. (LRMR)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Start

Phase3_Start: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia

October 26, 2026

LRMR overview →

Company: Larimar Therapeutics, Inc. (LRMR)